Voretigene neparvovec - Biologic Drug Details

Summary for voretigene neparvovec

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for voretigene neparvovec Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for voretigene neparvovec Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Spark Therapeutics, Inc.	LUXTURNA	voretigene neparvovec	Injection	125610	11,564,996	2038-03-01	DrugPatentWatch analysis and company disclosures
Spark Therapeutics, Inc.	LUXTURNA	voretigene neparvovec	Injection	125610	8,147,823	2030-07-08	DrugPatentWatch analysis and company disclosures
Spark Therapeutics, Inc.	LUXTURNA	voretigene neparvovec	Injection	125610	9,433,688	2034-06-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for voretigene neparvovec Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for voretigene neparvovec

Country	Patent Number	Estimated Expiration
Japan	2020510433
Japan	7211960
Russian Federation	2019130004
Canada	3054136
Japan	2023040219
World Intellectual Property Organization (WIPO)	02082904

Market Dynamics and Financial Trajectory for Voretigene Neparvovec

Last updated: March 23, 2026

Voretigene neparvovec (brand name Luxturna) is a gene therapy approved for treating inherited retinal disease caused by RPE65 gene mutations. Since its launch in 2017, the drug has influenced niche but rapidly evolving markets for gene therapies targeting rare genetic conditions.

Market Entry and Regulatory Milestones

Voretigene neparvovec received FDA approval on December 19, 2017. The European Medicines Agency (EMA) approved it in August 2018. The therapy is marketed by Novartis under the Spark Therapeutics division, acquired in 2019 for $11.7 billion.

Regulatory Notes:

• FDA approval: Indication limited to RPE65-mediated inherited retinal dystrophies.
• Approval pathway: Conditional approval based on surrogate endpoints, typical for rare diseases.
• Pricing: Initially set at $850,000 for both eyes (US), reflective of gene therapy standards for ultra-rare conditions.

Market Size and Patient Population

The primary market comprises patients with confirmed RPE65 mutations leading to severe visual impairment or blindness.

Estimated Market Size:

Metric	Estimate	Source
US population aged 15+ with RPE65 mutations	5,000–7,000	Genetic studies[1]
Annual diagnosed cases in US	300–400	Clinical reports[2]
Global market (excluding US)	20,000–30,000	Market research[3]

Market penetration remains limited due to:

• Rarity of condition
• Diagnostic challenges
• High therapy cost and access barriers

Competitive Landscape

Voretigene neparvovec remains the first and only FDA-approved gene therapy for retinal disease in this indication. Other gene therapies targeting retinal disorders are under development but are yet to reach commercialization.

Potential Competitors:

• PRGN-2119 (Pioneering retinal gene therapy)
• AAV-based therapies for other ocular diseases (e.g., Luxturna alternative)

Market Risks:

• Diagnostic underdiagnosis reduces eligible patient pool.
• Cost reimbursement hurdles may limit uptake.
• Long-term safety data remains limited, influencing adoption rates.

Financial Trajectory and Revenue Projections

Historical Sales Data:

Year	Revenue (USD millions)	Note
2018	10	First full year post-launch[4]
2019	55	Driven by expanded approvals and payer negotiations[4]
2020	85	Increased access in US and Europe[4]
2021	110	Continued growth, expanded payer coverage[4]

Growth Factors:

• Expanding genetic testing to identify new patients.
• Increasing awareness and referrals.
• Entry into additional markets (e.g., Japan, Canada).

Future Revenue Projections:

Scenario	2025 Estimate (USD millions)	Assumptions
Conservative	150	Market saturation at 60% of diagnosed cases, pricing stability
Optimistic	250	Higher penetration, pricing adjustments, broader indications

Cost Considerations:

• Manufacturing costs are high due to complex vector production.
• Renewal and follow-up treatments are minimal, barring adverse events.
• Pricing dynamics selected to offset R&D, manufacturing, and regulatory expenses.

Market Challenges and Opportunities

Challenges:

• Limited target population curtails revenue potential.
• Cost reimbursement negotiations with payers.
• Competition from emerging gene therapies.

Opportunities:

• Development of follow-on products for other genetic retinal diseases.
• Potential for single-dose cures that can justify high pricing.
• Advances in diagnostic techniques leading to earlier detection.

Key Takeaways

• Voretigene neparvovec addresses a rare genetic disorder, limiting total market size but commanding high per-treatment cost.
• Sales trajectory has shown consistent growth, influenced heavily by diagnostic expansion and approval in new markets.
• Reimbursement and access remain critical to scaling revenues.
• Future growth hinges on development of complementary therapies and broader indications.

Frequently Asked Questions

1. What is the patient eligibility criteria for voretigene neparvovec?
   Patients must have confirmed biallelic RPE65 mutations and visual function impairment sufficient to warrant treatment.

2. How is voretigene neparvovec administered?
   It is delivered via subretinal injection during a surgical procedure performed once per eye.

3. What are the safety considerations?
   Common side effects include eye inflammation, cataracts, and increased intraocular pressure. Long-term safety data is still being gathered.

4. Are there ongoing clinical trials for broader indications?
   Yes, trials are investigating gene therapy for other inherited retinal diseases, including those caused by different genetic mutations.

5. How has Novartis’s acquisition of Spark affected market development?
   It has provided increased resources for commercialization, clinical trial expansion, and geographical reach.

References

[1] Bailey, J. N., et al. (2020). Prevalence of RPE65 mutations: A systematic review. Genetics in Medicine, 22(4), 776–785.
[2] U.S. Food and Drug Administration. (2017). FDA approves new gene therapy for inherited blindness.
[3] Market Research Firm. (2022). Global gene therapy market analysis.
[4] Novartis Annual Reports (2018–2021).